SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $100,000 in Losses from Investment in Sanofi to Contact B...
06 Januar 2014 - 11:50PM
Business Wire
Brower Piven, A Professional Corporation announces that a class
action lawsuit has been commenced in the United States District
Court for the Southern District of New York on behalf of purchasers
of Sanofi (“Sanofi” or the “Company”) (NasdaqGM: GCVRZ) contingent
value rights (“CVRs”) during the period between March 6, 2012 and
November 7, 2013, inclusive (the “Class Period”).
If you have suffered a net loss from investment in Sanofi CVRs
purchased on or after March 6, 2012, and held through the
revelation of negative information on November 8, 2013, as
described below, at no cost to you, you may obtain additional
information about this lawsuit and your ability to become a lead
plaintiff by contacting Brower Piven at www.browerpiven.com, by
email at hoffman@browerpiven.com, by calling 410/415-6616, or at
Brower Piven, A Professional Corporation, 1925 Old Valley Road,
Stevenson, Maryland 21153. Attorneys at Brower Piven have combined
experience litigating securities and class action cases of over 60
years.
No class has yet been certified in the above action. Members of
the Class will be represented by the lead plaintiff and counsel
chosen by the lead plaintiff. If you wish to choose counsel to
represent you and the Class, you must apply to be appointed lead
plaintiff no later than February 10, 2014 and be selected by the
Court. The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a
settlement and how much of a settlement to accept for the Class in
the action. The lead plaintiff will be selected from among
applicants claiming the largest loss from investment in the Company
during the Class Period.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of the defendants’
failure to disclose during the Class Period that the Company’s 323
and 324 trials for Lemtrada, a treatment for multiple sclerosis,
contained high levels of placebo effect and observer bias which
tainted the results and thereby lowered the likelihood of Lemtrada
being approved by the U.S. Food and Drug Administration (“FDA”).
According to the complaint, following the issuance of a November 8,
2013 briefing report by the FDA Advisory Committee on Peripheral
and Central Nervous System Drugs, which criticized the Company’s
submission to the FDA and expressed significant concerns regarding
the safety profile of Lemtrada and the adequacy of the efficacy
data, the value of Sanofi CVRs declined significantly.
If you choose to retain counsel, you may retain Brower Piven
without financial obligation or cost to you, or you may retain
other counsel of your choice. You need take no action at this time
to be a member of the class.
Brower Piven, A Professional CorporationStevenson,
MarylandCharles J. Piven, 410-415-6616hoffman@browerpiven.com
Sanofi (NASDAQ:GCVRZ)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Sanofi (NASDAQ:GCVRZ)
Historical Stock Chart
Von Jun 2023 bis Jun 2024